New breast cancer targets to be evaluated by Domainex
This article was originally published in Scrip
Tankyrase and IKK-epsilon, two new potential drug targets in breast cancer, are to be the subject of a research collaboration between the UK drug discovery company Domainex and the Institute of Cancer Research's Breakthrough Breast Cancer Research Centre. Domainex will apply its virtual hit-finding process, LeadBuilder, to the targets, and the collaborators will then partner with larger organisations to develop them further. The Breast Cancer Research Centre is led by Professor Alan Ashworth and has 120 researchers focused on the study of the disease.